1289093-31-7Relevant articles and documents
Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain
Luo, Guanglin,Chen, Ling,Easton, Amy,Newton, Amy,Bourin, Clotilde,Shields, Eric,Mosure, Kathy,Soars, Matthew G.,Knox, Ronald J.,Matchett, Michele,Pieschl, Rick L.,Post-Munson, Debra J.,Wang, Shuya,Herrington, James,Graef, John,Newberry, Kimberly,Sivarao, Digavalli V.,Senapati, Arun,Bristow, Linda J.,Meanwell, Nicholas A.,Thompson, Lorin A.,Dzierba, Carolyn
, p. 831 - 856 (2019/01/21)
3-Aryl-indole and 3-aryl-indazole derivatives were identified as potent and selective Nav1.7 inhibitors. Compound 29 was shown to be efficacious in the mouse formalin assay and also reduced complete Freund's adjuvant (CFA)-induced thermal hyper
ACYL SULFONAMIDE NaV1.7 INHIBITORS
-
Page/Page column 24, (2017/11/15)
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
-
Paragraph 00214, (2015/04/22)
The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. (Ia); as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.